This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
STENTYS (FR0010949404 – STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced its audited annual results for the 2012 financial year to 31 December 2012 as approved by the Board of Directorson 27 March 2013.
2012 annual results: further sales growth while controlling costs
€ thousands – IFRS*
31 December 2012
31 December 2011
Operating expenses before share-based payment **
Operational loss before share-based payment
*Audited data ** Including cost of sales
As announced on 24 January 2013, STENTYS recorded annual revenues of €2.5 million in 2012, an increase of 77% on the previous year. The sales performance recorded in 2012 continues to indicate substantial appeal for the STENTYS Self-Apposing stent amongst cardiologists in countries where it has been pre-marketed.